Arch Therapeutics, Inc. (ARTH)

1.1900 -0.0675 (-5.37%) 收市：02:42PM EDT

Arch Therapeutics, Inc.

235 Walnut Street
Suite 6
Framingham, MA 01702
United States
617 431 2313
https://www.archtherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 8

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Terrence W. Norchi M.D.	Co-Founder, Chairman, President & CEO	450.5k	無	1965
Mr. Michael S. Abrams	CFO & Treasurer	325k	無	1970
Dr. Rutledge Ellis-Behnke Ph.D.	Co-Founder & Scientific Advisor	無	無	無
Mr. Shawn Carlson	Vice President of Sales	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

公司管治

截至 無 止，Arch Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。